We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Sudden Cardiac Death Stratification in Myotonic Dystrophy Type 1 Patients
Previous Study | Return to List | Next Study

Sudden Cardiac Death Stratification in Myotonic Dystrophy Type 1 Patients (ACADEMY 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03784586
Recruitment Status : Recruiting
First Posted : December 24, 2018
Last Update Posted : June 18, 2021
Information provided by (Responsible Party):
Vincenzo Russo, University of Campania "Luigi Vanvitelli"

Brief Summary:
The aim of the study is to evaluate if the electrophysiological study (EPS) guided therapy, including the prophylactic implantation of implantable cardioverter defibrillator (ICD), in inducible patients, is able to improve survival in comparison with conventional therapy (CONV strategy) in Myotonic Dystrophy type 1 patients with conduction disorders.

Condition or disease
Myotonic Dystrophy 1 Sudden Cardiac Death

Detailed Description:

Trial design:

This is a double-arm prospective observational study.

Patient population:

To be included in the study, DM1 patients had to have at least 18 years old, LVEF >35% on two-dimensional echocardiography, permanent pacing indication after non-invasive electrocardiographic evaluation or invasive EPS evaluation, according to the current guidelines. The following exclusion criteria were applied: electrolyte imbalance, thyroid disorders, prior cardiac surgery, prior cardiac arrest, prior spontaneous sustained ventricular arrhythmias, absuntion of antiarrhythmic drugs or medication known to affect cardiac conduction. All eligible DM1 patients underwent EPS for programmed ventricular stimulation; those in whom a sustained ventricula arrhythmia was inducible underwent subsequently ICD implantation. Non-inducible DM1 patients did not receive an ICD and underwent pacemaker implantation.


The primary endpoint was all-cause mortality. Secondary end-points were sudden death (SD), death due to cardiac arrhythmias, ICD interventions and arrhythmic events in implanted patients.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 70 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: The Electrophysiological Study Guided ICD Strategy in Prevention of Arrhythmic Cardiac Death in Myotonic Dystrophy Type 1 Patients With Conduction System Disease (ACADEMY 1 Study)
Actual Study Start Date : February 1, 2012
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : May 31, 2023

Positive EPS - ICD
Patients with inducible sustained ventricular tachycardia or ventricular fibrillation at EPS evaluation underwent ICD implantation
Negative EPS - PMK
All non inducible patients underwent PMK implantation

Primary Outcome Measures :
  1. Sudden Cardiac Death [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. All-cause mortality [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
MD1 patients with permanent pacing indication and needed of sudden cardiac death screening.

Inclusion Criteria:

  • MD1 diagnosis genetically confirmed
  • LVEF >35% on two-dimensional echocardiography
  • Permanent pacing indication according to the current guidelines

Exclusion Criteria:

  • Electrolyte imbalance
  • Thyroid disorders
  • Prior cardiac surgery
  • Prior cardiac arrest
  • Prior spontaneous sustained ventricular arrhythmias

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03784586

Layout table for location contacts
Contact: Vincenzo Russo, MD,PhD 0817064149 v.p.russo@libero.it
Contact: Andrea Antonio Papa, MD 0817065158 andreaantoniopapa@libero.it

Layout table for location information
Vincenzo Russo Recruiting
Naples, Italy, 80136
Sponsors and Collaborators
University of Campania "Luigi Vanvitelli"
Layout table for additonal information
Responsible Party: Vincenzo Russo, MD, PhD, Assistant Professor, University of Campania "Luigi Vanvitelli"
ClinicalTrials.gov Identifier: NCT03784586    
Other Study ID Numbers: 01_MD1
First Posted: December 24, 2018    Key Record Dates
Last Update Posted: June 18, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Vincenzo Russo, University of Campania "Luigi Vanvitelli":
electrophisiological study
primary prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
Myotonic Dystrophy
Death, Sudden, Cardiac
Heart Arrest
Heart Diseases
Death, Sudden
Muscular Dystrophies
Myotonic Disorders
Pathologic Processes
Cardiovascular Diseases
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Genetic Diseases, Inborn